Development of Nanobodies against Pseudomona aeruginosa and Staphylococcus aureus and evaluation as immunotherapeutics

Project Information

CF.Nbs.PA-SA

Grant agreement ID: 101154094

DOI 10.3030/101154094

EC signature date 22 March 2024

Start date 1 September 2024

End date 31 August 2026

Funded under

• Marie Skłodowska-Curie Actions (MSCA)

Total cost No data

EU contribution € 181 152,96

Coordinated by

CONSORCIO CENTRO DE INVESTIGACION BIOMEDICA EN RED M.P.
Spain

Objective

Cystic fibrosis (CF) is a genetic disorder, impacting various organs due to CFTR gene mutations. Lungs are severely affected by secretions, harboring bacteria, causing recurrent, chronic, and often fatal infections in 90% of CF patients. Globally, around 105,000 people across 94 countries suffer from CF, with an improved median survival age of 30 to 40 years, yet poor quality of life persists due to daily treatment needs.
Staphylococcus aureus (SA) and Pseudomonas aeruginosa (PA) are the primary pathogens isolated from CF patients' respiratory tracts, leading to most CF-related deaths. Their factors of virulence contributes to extensive damage, and despite intensive treatments, infections persist, fostering antimicrobial resistance. Antibiotic resistance claims over 35,000 lives yearly in the EU alone, underscoring the urgent need for novel therapeutics to combat SA and PA infections.
Nanobodies (Nbs) offer revolutionary immunotherapy potential due to their unique attributes. They are ten times smaller than conventional antibodies, maintaining strong recognition capability at nanomolar levels. Nbs exhibit low immunogenicity, rapid tissue penetration, and can target previously inaccessible antigen sites. Their small size provides enhanced stability, thermal resistance, reversibility of unfolding, proteolytic resistance, and high solubility.
Given the prevalence and severe consequences of SA and PA infections, the central aim of the project is to develop therapeutic Nbs to mitigate the impact of these infections and improve the quality of life for CF patients.

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.

• natural sciences › biological sciences › microbiology › bacteriology
• natural sciences › biological sciences › genetics › mutation

You need to log in or register to use this function

Keywords

• Nanobodies
• Immunotherapeutics
• Pseudomona aeruginosa
• Staphylococcus aureus
• Cystic Fibrosis

Programme(s)

• HORIZON.1.2 - Marie Skłodowska-Curie Actions (MSCA) Main Programme

Topic(s)

• HORIZON-MSCA-2023-PF-01-01 - MSCA Postdoctoral Fellowships 2023

Call for proposal

HORIZON-MSCA-2023-PF-01

Funding Scheme

HORIZON-TMA-MSCA-PF-EF - HORIZON TMA MSCA Postdoctoral Fellowships - European Fellowships

Coordinator

CONSORCIO CENTRO DE INVESTIGACION BIOMEDICA EN RED M.P.

• Net EU contribution: € 181 152,96
• Address: CALLE MONFORTE DE LEMOS 5 ; 28029 Madrid ; Spain
• Region: Comunidad de Madrid › Comunidad de Madrid › Madrid
• Activity type: Research Organisations
• Total cost: No data